Active Immunotherapy: Ready For Prime Time by admin | Jul 23, 2026 | Investor Presentations, Investors
Scancell Financial Year 2026 Interim Results by chantal | Jan 29, 2026 | Investor Presentations, Investors, Presentations
ESMO IO: Refining Standard of Care in Advanced Melanoma by chantal | Dec 12, 2025 | Investor Presentations
CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive by chantal | Dec 12, 2025 | Investor Presentations
SCOPE Data Update: 11 December 2025 by alex | Dec 12, 2025 | Immunobody, Investor Presentations, iSCIB1+, SCIB1
Presentation of Year End Results: 11 September 2025 by chantal | Sep 12, 2025 | Investor Presentations
